WO2019151829A1 - 장세척 조성물 - Google Patents
장세척 조성물 Download PDFInfo
- Publication number
- WO2019151829A1 WO2019151829A1 PCT/KR2019/001456 KR2019001456W WO2019151829A1 WO 2019151829 A1 WO2019151829 A1 WO 2019151829A1 KR 2019001456 W KR2019001456 W KR 2019001456W WO 2019151829 A1 WO2019151829 A1 WO 2019151829A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- content
- ascorbate
- specifically
- solution
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Definitions
- the present invention relates to an enteric wash composition comprising polyethylene glycol and an ascorbate component.
- Colorectal cancer is a cancer whose steadily increasing incidence has been seen since the 1980s. According to the main cause of death reported by the National Statistical Office in 2016, the number of colorectal cancer deaths is higher than the number of gastric cancer deaths. It is counted.
- the representative enteric cleaners including polyethylene glycol which is a representative component of the enteric cleaner
- all 4 L of the liquid solution should be taken, and the products have a taste that is difficult to take, such as salty taste, awkward taste.
- the amount of the drug to be taken is too high to take, many patients failed to take the bowel cleansing agent even before the colonoscopy, the test was not properly performed.
- there were problems such as nausea, vomiting and other side effects.
- the present inventors have tried to solve the above problems, while reducing the dose of the drug solution shows an excellent bowel cleaning effect, can easily consume a considerable amount of the drug solution required as an intestinal cleansing agent, and completed a safe bowel cleansing composition.
- It is an object of the present invention to provide an enteric wash composition comprising polyethylene glycol and an ascorbate component.
- the present invention provides a long-wash composition comprising polyethylene glycol (PEG) and ascorbate component.
- PEG polyethylene glycol
- the present invention provides a long wash solution containing polyethylene glycol (PEG) and ascorbate component.
- PEG polyethylene glycol
- the content of the components included in the long cleansing composition and the long cleansing solution of the present invention may be expressed in units of g (gram), mole, g / L, M (molarity), and the like.
- the average molecular weight of the polyethylene glycol (PEG) of the present invention may be the average molecular weight of the conventional polyethylene glycol used in the long cleansing composition or the long clean solution, it may be 100 to 10,000, but is not limited thereto.
- the average molecular weight of the polyethylene glycol may be 2,000 to 8,000, specifically 2,000 to 5,000, it may be more specifically 3,000 to 4,000.
- the polyethylene glycol of the present invention may be polyethylene glycol 3350 (PEG3350) or polyethylene glycol 4000 (PEG4000).
- the content of the polyethylene glycol included in the long wash composition of the present invention may be 55 mmol or less, and specifically 50 mmol or less. In addition, the content of the polyethylene glycol may be 40 mmol or more, specifically 45 mmol or more. The content of the polyethylene glycol included in the long wash composition of the present invention may be 40 to 55 mmol, specifically 45 to 50 mmol, and more specifically 47.76 mmol.
- the content of the polyethylene glycol contained in the long wash composition of the present invention may be 180 g or less, and specifically 170 g or less.
- the content of the polyethylene glycol may be 140 g or more, specifically 150 g or more.
- the content of the polyethylene glycol included in the long cleansing composition of the present invention may be 140 to 180 g, specifically 150 to 170 g, and more specifically 160 g.
- the content of the polyethylene glycol 3350 may be 180 g or less, specifically 170 g or less.
- the content of the polyethylene glycol 3350 may be 140 g or more, specifically 150 g or more.
- the content of the polyethylene glycol 3350 included in the long cleansing composition of the present invention may be 140 to 180 g, specifically 150 to 170 g, and more specifically 160 g.
- the content (g) of polyethylene glycol included in the long cleansing composition of the present invention may vary depending on the average molecular weight of polyethylene glycol.
- the content of the polyethylene glycol included in the long cleansing solution may be 55 mM or less, and specifically 50 mM or less.
- the content of the polyethylene glycol may be 40 mM or more, specifically 45 mM or more.
- the content of the polyethylene glycol included in the enteric wash solution of the present invention may be 40 to 55 mM, specifically 45 to 50 mM, and more specifically 47.76 mM.
- the content of the polyethylene glycol contained in the long cleansing solution may be 180 g / L or less, and specifically 170 g / L or less.
- the content of the polyethylene glycol may be 140 g / L or more, specifically 150 g / L or more.
- the content of the polyethylene glycol contained in the long wash solution of the present invention may be 140 to 180 g / L, specifically 150 to 170 g / L, may be more specifically 160 g / L.
- the content of the polyethylene glycol 3350 contained in the long cleansing solution may be 180 g / L or less, specifically 170 g / L or less have.
- the content of the polyethylene glycol 3350 may be 140 g / L or more, specifically 150 g / L or more.
- the content of the polyethylene glycol 3350 in the long wash solution of the present invention may be 140 to 180 g / L, specifically 150 to 170 g / L, and more specifically 160 g / L.
- the content (g / L) of polyethylene glycol included in the long cleansing composition of the present invention may vary depending on the average molecular weight of polyethylene glycol.
- the polyethylene glycol contained in the bowel cleansing composition and the bowel cleansing solution of the present invention should be included in an amount sufficient to exert a sufficient long cleansing effect. Losing problems may occur, and excessive osmotic pressure of the enteric cleaner may cause safety problems.
- the ascorbate component of the present invention includes ascorbic acid and / or ascorbate, and may specifically include both ascorbic acid and ascorbate.
- the molecular weight of the ascorbic acid may be 176 g / mol.
- Ascorbate contained in the enteric cleaning composition or enteric cleaning solution of the present invention may be included in the form of an alkali metal salt and / or an alkaline earth metal salt.
- Specific types of salts of ascorbate may be any one or more selected from the group including sodium salt, potassium salt, magnesium salt and calcium salt, but are not limited thereto.
- the ascorbate may be sodium ascorbate (sodium ascorbate, molecular weight 198 g / mol).
- the ascorbate component included in the enteric cleaning composition or enteric cleaning solution of the present invention may be included in the form of ester ascorbic acid fatty acid ester (ester ascorbic acid fatty acid ester), and a surfactant component for solubilizing it may be used. Can be.
- the content of the ascorbate component included in the long cleansing composition of the present invention may be less than 300 mmol, specifically 290 mmol or less.
- the content of the ascorbate component may be 250 mmol or more, and specifically 270 mmol or more.
- the content of the ascorbate component included in the long wash composition of the present invention may be 250 mmol or more and less than 300 mmol, specifically 270 to 290 mmol, and more specifically 278.16 mmol.
- the content of the ascorbate component included in the long cleansing composition of the present invention may be less than 55 g, specifically 54 g or less, and more specifically 53 g or less.
- the content of the ascorbate component may be 45 g or more, specifically 48 g or more.
- the content of the ascorbate component included in the long wash composition of the present invention may be 45 g or more and less than 55 g, specifically 45 to 54 g, specifically 48 to 53 g, more specifically 50 may be g.
- the content of ascorbate component included in the long wash solution may be less than 300 mM, specifically, may be 290 mM or less.
- the content of the ascorbate component may be 250 mM or more, specifically 270 mM or more.
- the content of the ascorbate component included in the enteric wash solution of the present invention may be 250 mM or more and less than 300 mM, specifically 270 to 290 mM, and more specifically 278.16 mM.
- the content of ascorbate contained in the long cleansing solution may be less than 55 g / L, specifically 54 g / L or less, and more specifically, May be 53 g / L or less.
- the content of the ascorbate component may be 45 g / L or more, specifically 48 g / L or more.
- the content of the ascorbate component included in the enteric wash solution of the present invention may be 45 g / L or more and less than 55 g / L, specifically 45 to 54 g / L, and specifically 48 to 53 g / L It may be, more specifically 50 g / L.
- the ascorbate component may have toxicity problems such as kidney failure when excessively ingested, and may cause nausea, nausea, and heartburn due to irritation of the stomach. Therefore, the ascorbate component of the present invention may be included within the above range, the content of the ascorbate component may be preferably 53 g / L or less, more specifically 50 g / L or less.
- the molar ratio of the polyethyleneglycol and ascorbate component included in the long cleansing composition or the long cleansing solution of the present invention may be 1: 4.5 to 1: 7.5, specifically 1: 5.5 to 1: 6, even more specifically 1: May be 5.82.
- the weight ratio of the polyethyleneglycol and ascorbate component included in the long cleansing composition or the long cleansing solution of the present invention may be 2.5: 1 to 4: 1, specifically 3: 1 to 3.5: 1, and more specifically 3.2: 1. have.
- the intestinal cleansing composition or intestinal cleansing solution of the present invention not only shows an excellent intestinal cleansing effect, but also mucosal damage, blood test values It shows excellent safety with improved fluctuations.
- the enteric wash solution of the present invention is characterized in that the mortality, gastric mucosal damage and AST (Asparate aminotransferase), ALT, in blood tests in animal experiments compared to enteric wash solutions with a higher weight ratio of ascorbate component to polyethylene glycol (Alkaine aminotransferase), urea nitrogen (BUN), creatinine (Creatinine), red blood cells (RBC), hemoglobin (HGB), mean corpuscular hemoglobin concentration (MCHC), hematocrit , HCT) and the like, the concentration fluctuations are significantly low, it was confirmed that the long-wash solution with excellent safety (see Experimental Example 2, etc.).
- the ascorbate component of the present invention may comprise ascorbic acid, ascorbate or mixtures thereof.
- the ascorbate component of the present invention preferably comprises both ascorbic acid and ascorbate.
- the ascorbate may be sodium ascorbate.
- the content of ascorbic acid may be 255 mmol or less, specifically 240 mmol or less, and the content of ascorbate may be 55 mmol or less, specifically, It may be up to 50 mmol.
- the content of ascorbic acid may be 200 mmol or more, specifically 220 mmol or more, and the content of ascorbate may be 40 mmol or more, and specifically 45 mmol or more.
- the content of the ascorbic acid included in the enteric wash composition of the present invention comprising ascorbic acid and ascorbate may be 200 to 255 mmol, specifically 220 to 240 mmol, more specifically 230.68 mmol, The content of ascorbate may be 40 to 55 mmol, specifically 45 to 50 mmol, and more specifically 47.47 mmol.
- the content of ascorbic acid may be 45 g or less, specifically 43 g or less, and the content of sodium ascorbate may be 11 g or less. Specifically, it may be 10 g or less.
- the content of ascorbic acid may be 35 g or more, specifically 39 g or more, and the content of sodium ascorbate may be 8 g or more, and specifically 9 g or more.
- the content of the ascorbic acid included in the enteric wash composition of the present invention comprising ascorbic acid and sodium ascorbate may be 35 to 45 g, specifically 39 to 43 g, more specifically 40.6 g
- the content of sodium ascorbate may be 8 to 11 g, specifically 9 to 10 g, and more specifically 9.4 g.
- the ascorbate included in the enteric wash composition of the present invention may be included in an appropriate content (g, g / L) range depending on the form of ascorbate.
- the content of ascorbic acid contained in the enteric wash solution may be 255 mM or less, specifically 240 mM or less, The content of ascorbate may be 55 mM or less, specifically 50 mM or less.
- the content of ascorbic acid may be 200 mM or more, specifically 220 mM or more, and the content of ascorbate may be 40 mM or more, and specifically 45 mM or more.
- the content of the ascorbic acid contained in the enteric wash solution of the present invention containing ascorbic acid and ascorbate may be 200 to 255 mM, specifically 220 to 240 mM, more specifically 230.68 mM, The content of ascorbate may be 40 to 55 mM, specifically 45 to 50 mM, and more specifically 47.47 mM.
- the content of ascorbic acid contained in the long cleansing solution may be 45 g / L or less, specifically 43 g / L
- the amount of sodium ascorbate may be 11 g / L or less, and specifically 10 g / L or less.
- the content of ascorbic acid may be 35 g / L or more, specifically 39 g / L or more
- the content of sodium ascorbate may be 8 g / L or more, specifically 9 g / L or more. .
- the content of the ascorbic acid contained in the enteric washing solution containing ascorbic acid and sodium ascorbate of the present invention may be 35 to 45 g / L, specifically 39 to 43 g / L, more specifically 40.6 It may be g / L, the content of the sodium ascorbate may be 8 to 11 g / L, specifically 9 to 10 g / L, may be more specifically 9.4 g / L.
- the molar ratio of ascorbic acid and ascorbate included as an ascorbate component of the enteric cleaning composition or enteric cleaning solution of the present invention may be 4: 1 to 6: 1, specifically 4: 1 to 5: 1, more specifically 4.5: 1 to 5: 1, even more specifically 4.8: 1 to 4.9: 1.
- the weight ratio of ascorbic acid and sodium ascorbate included as an ascorbate component of the long cleansing composition or long cleansing solution of the present invention may be 3.5: 1 to 5: 1, specifically 4: 1 to 5: 1, more specifically 4 to 1: 4.5: 1, and more specifically, 4.2: 1 to 4.4: 1.
- the enteric cleaning solution of the present invention may be used for Na + , AST (Asparate aminotransferase), ALT (Alkaine aminotransferase), etc. Significantly less numerical changes in blood tests, it can be used as an enteric cleaner with excellent safety.
- the enteric wash solution of the present invention contains the same polyethyleneglycol and ascorbate component contents but has a higher content ratio of sodium ascorbate than the enteric wash solution in animal experiments compared to the enteric wash solution of the present invention. The amount of change such as AST value and Na + value was remarkably small, confirming that the solution was excellent in safety (see Example 2 and the like).
- the enteric cleaning composition or enteric cleaning solution of the present invention not only exhibits an excellent enteric cleaning effect including ascorbic acid and ascorbate in the above range, but also improves the taste of the enteric cleaning solution to reduce heterogeneity and rejection when the solution is taken, and is sufficient intestine. It is possible to achieve the convenience of taking a well ingested large amount of the solution necessary to achieve the cleaning effect.
- the present invention provides an enteric wash composition or enteric wash solution comprising polyethylene glycol, an ascorbate component and sulfate.
- polyethylene glycol and ascorbate components their content and concentration, and the like contained in the composition or solution is the same as described above.
- Sulfates of the invention may be included in the form of their alkali metal salts and / or alkaline earth metal salts.
- the sulfate may be any one or more selected from the group consisting of sodium sulfate, potassium sulfate, and magnesium sulfate, but is not limited thereto.
- the sulfate may be sodium sulfate, and the sulfate such as sodium sulfate may be an anhydride or a hydrate.
- the sulfate of the present invention may be sulfate anhydride.
- the content of sodium sulfate in the present invention is described based on the content of sodium sulfate anhydride (molecular weight 142 g / mol), the content of sodium sulfate hydrate may vary depending on the molecular weight of sodium sulfate hydrate.
- the content of sodium sulfate is 10 g as anhydride and 10 g as sodium anhydride means 10 g as anhydrous sodium sulfate and 18.87 g as sodium sulfate heptahydrate (molecular weight 268 g / mol). That is, the content of sodium sulfate hydrate is calculated in consideration of the molecular weight of the hydrate to be 10 g in the form of anhydride.
- the sulfate is included in the bowel cleansing composition or bowel cleansing solution of the present invention to exhibit a long cleansing effect, and the sulfate ions generated from the sulfate can inhibit the intestinal absorption of sodium ions and minimize the absorption and excretion of water and electrolyte. have.
- the amount of sulfate contained in the long wash composition of the present invention may be 140 mmol or less, and specifically 130 mmol or less.
- the content of the sulfate may be 110 mmol or more, specifically 120 mmol or more.
- the sulfate content included in the long wash composition of the present invention may be 110 to 140 mmol, specifically 120 to 130 mmol, and more specifically 126.76 mmol.
- the content of the sodium sulfate contained in the long cleansing composition of the present invention is sodium sulfate
- the content of the sodium sulfate may be 20 g or less as an anhydride, specifically 18.5 g or less.
- the content of the sodium sulfate may be 16 g or more as an anhydride, specifically 17.5 g or more.
- the content of the sodium sulfate contained in the long wash composition of the present invention may be 16 to 20 g as an anhydride, specifically 17.5 to 18.5 g, and more specifically 18 g.
- the content (g) of the sulfate is not limited to the above range, and may be included in an appropriate range depending on the type of sulfate included.
- the amount of sulfate contained in the long cleansing solution may be 140 mM or less, and specifically 130 mM or less.
- the content of the sulfate may be 110 mM or more, specifically 120 mM or more.
- the amount of the sulfate contained in the enteric wash solution of the present invention may be 110 to 140 mM, specifically 120 to 130 mM, and more specifically 126.76 mM.
- the content of sodium sulfate included in the long wash solution may be 20 g / L or less as an anhydride, and specifically 18.5 g / L or less.
- the content of the sodium sulfate may be 16 g / L or more as an anhydride, specifically 17.5 g / L or more.
- the content of the sodium sulfate in the enteric wash solution containing sodium sulfate of the present invention may be 16 to 20 g / L as an anhydride, specifically 17.5 to 18.5 g / L, and more specifically 18 g / L day Can be.
- Sulfate contained in the bowel cleansing composition or the bowel cleansing solution of the present invention may be included in a molar ratio of 2 to 3.5 times compared to polyethylene glycol, in particular in the molar ratio of 2.5 to 3 times, more specifically, in consideration of the long cleaning effect and safety. May be included in a molar ratio of 2.65 times.
- the weight ratio of polyethylene glycol and sodium sulfate contained in the long-wash composition or the long-wash solution of the present invention may be 7: 1 to 12: 1, specifically 8: 1 to 10: 1, more specifically 8.5: 1 to 9.5 : 1, more specifically 8.89: 1.
- the bowel cleansing effect is better than the long cleansing solution having a different content ratio, and the numerical value on the blood test is less, thereby ensuring safety. Has the advantage.
- the present invention provides enteric cleaning compositions or enteric cleaning solutions comprising polyethylene glycol, ascorbate components, sulfates and electrolytes.
- the solution provided by the long cleansing composition or the long cleansing solution has a large volume (dose) ingested by the patient to reduce the absorption or loss of the electrolyte and to secure safety to minimize problems such as dehydration due to the ingestion of high volume solutions. It may comprise an electrolyte in an appropriate content and / or concentration range.
- the electrolyte of the present invention may include alkali metal salts and / or alkaline earth metal salts, and the like.
- the electrolyte of the present invention is salts of sodium, salts of potassium, salts of calcium, salts of magnesium, salts of chloride, salts of iodine iodide), salts of bicarbonate and salts of carbonate may be one or more selected from the group including, but not limited to.
- the electrolyte of the present invention may be sodium chloride (NaCl, molecular weight 58.5 g / mol) and / or potassium chloride (KCl, molecular weight 74.55 g / mol), more specifically the electrolyte of the present invention may be sodium chloride and potassium chloride.
- the content of the electrolyte included in the long cleansing composition of the present invention may be 0.1 to 10 g.
- Specific electrolytes included in the long cleansing composition of the present invention may include sodium chloride and potassium chloride.
- the content of sodium chloride contained in the long wash composition may be 3.5 g or less, and specifically 3 g or less.
- the sodium chloride content may be 2 g or more, specifically 2.5 g or more.
- the content of sodium chloride included in the long wash composition of the present invention may be 2 to 3.5 g, specifically 2.5 to 3 g, and more specifically 2.7 g.
- the content of sodium chloride contained in the long wash composition may be 60 mmol or less, specifically 50 mmol or less.
- the content of sodium chloride may be at least 35 mmol, specifically 40 mmol or more.
- the sodium chloride content included in the long wash composition of the present invention may be 35 to 60 mmol, specifically 40 to 50 mmol, and more specifically 46.15 mmol.
- the content of sodium chloride contained in the long cleansing solution may be 3.5 g / L or less, and specifically 3 g / L or less.
- the content of sodium chloride may be 2 g / L or more, specifically 2.5 g / L or more.
- the content of the sodium chloride contained in the enteric wash solution of the present invention may be 2 to 3.5 g / L, specifically 2.5 to 3 g / L, and more specifically 2.7 g / L.
- the content of sodium chloride contained in the long wash solution may be 60 mM or less, specifically, 50 mM or less.
- the content of sodium chloride may be 35 mM or more, specifically 40 mM or more.
- the content of the sodium chloride contained in the enteric wash solution of the present invention may be 35 to 60 mM, specifically 40 to 50 mM, and more specifically 46.15 mM.
- the content of potassium chloride contained in the long wash composition is preferably 2 g or less, specifically 1.5 g or less, more specifically 1.2 g or less.
- the content of potassium chloride may be 0.5 g or more, specifically 0.8 g or more.
- the content of potassium chloride included in the long wash composition of the present invention may be 0.5 to 2 g, specifically 0.5 to 1.5 g, more specifically 0.8 to 1.2 g, and more specifically 1 g. .
- the content of potassium chloride included in the long wash composition is preferably 27 mmol or less, specifically 20 mmol or less, and more specifically 16 mmol or less.
- the content of potassium chloride may be 7 mmol or more, specifically 10 mmol or more.
- the content of the potassium chloride contained in the enteric wash solution of the present invention may be 7 to 27 mmol, specifically 7 to 20 mmol, more specifically 10 to 16 mmol, and more specifically 13.41 mmol have.
- the content of potassium chloride contained in the long cleansing solution may be 2 g / L or less, specifically 1.5 g / L or less, and more specifically 1.2 g / L. It may be less than or equal to L.
- the potassium chloride content may be 0.5 g / L or more, and specifically 0.8 g / L or more.
- the content of potassium chloride contained in the enteric wash solution of the present invention may be 0.5 g / L to 2 g / L, specifically 0.5 to 1.5 g / L, and more specifically 0.8 to 1.2 g / L. , More specifically, 1 g / L.
- the content of potassium chloride contained in the long wash solution may be 27 mM or less, specifically 20 mM or less, more specifically 16 mM or less. .
- the content of potassium chloride may be 7 mM or more, specifically 10 mM or more.
- the content of the potassium chloride contained in the enteric wash solution of the present invention may be 7 to 27 mM, specifically 7 to 20 mM, more specifically 10 to 16 mM, more specifically 13.41 mM may be have.
- the bowel cleansing solution of the present invention exhibits an excellent bowel cleansing effect by adjusting the content of potassium chloride to 2 g / L or less, specifically 1 g / L or less, and ensuring safety by suppressing changes in blood electrolyte (sodium, etc.) concentration. Contributes to providing an enteric wash solution.
- the present invention provides a long wash composition comprising 40 to 55 mmol of polyethylene glycol, 250 mmol or more and less than 300 mmol of ascorbate component, 110 to 140 mmol of sulphate, 35 to 60 mmol of sodium chloride and 7 to 27 mmol of potassium chloride. to provide.
- the present invention comprises 140 to 180 g polyethylene glycol, 45 g or more and less than 55 g ascorbate component, 16 to 20 g sodium sulfate as an anhydride, 2 to 3.5 g sodium chloride and 0.5 to 2 g potassium chloride To provide a composition.
- the present invention provides a long wash composition
- a long wash composition comprising 140 to 180 g polyethylene glycol, 45 to 54 g ascorbate component, 16 to 20 g sodium sulfate as an anhydride, 2 to 3.5 g sodium chloride and 0.5 to 2 g potassium chloride. to provide.
- the present invention provides a long wash solution comprising 40 to 55 mM polyethylene glycol, 250 mM or more ascorbate component, 110 to 140 mM sulfate, 35 to 60 mM sodium chloride and 7 to 27 mM potassium chloride. to provide.
- the present invention provides 140 to 180 g / L polyethylene glycol, 45 g / L to 55 g / L ascorbate component, 16 to 20 g / L sodium sulfate as anhydride, 2 to 3.5 g / L sodium chloride and 0.5 It provides an enteric wash solution containing from 2 g / L potassium chloride.
- the present invention comprises 140 to 180 g / L polyethylene glycol, 45 to 54 g / L ascorbate component, 16 to 20 g / L sodium sulfate as anhydride, 2 to 3.5 g / L sodium chloride and 0.5 to 2 g / An intestinal wash solution comprising L of potassium chloride is provided.
- the present invention comprises 40 to 55 mmol polyethylene glycol, 200 to 255 mmol ascorbic acid, 40 to 55 mmol sodium ascorbate, 110 to 140 mmol sulfate, 35 to 60 mmol sodium chloride and 7 to 27 mmol potassium chloride It provides a long wash composition.
- the present invention comprises 140 to 180 g polyethylene glycol, 35 to 45 g ascorbic acid, 8 to 11 g sodium ascorbate, 16 to 20 g sodium sulfate as an anhydride, 2 to 3.5 g sodium chloride and 0.5 to 2 g potassium chloride It provides a long wash composition comprising a.
- the present invention includes 40 to 55 mM polyethylene glycol, 200 to 255 mM ascorbic acid, 40 to 55 mM sodium ascorbate, 110 to 140 mM sulfate, 35 to 60 mM sodium chloride and 7 to 27 mM potassium chloride. To provide an intestinal wash solution.
- the present invention comprises 140 to 180 g / L polyethylene glycol, 35 to 45 g / L ascorbic acid, 8 to 11 g / L sodium ascorbate, 16 to 20 g / L sodium sulfate as an anhydride, 2 to 3.5 g / L
- An enteral wash solution comprising sodium chloride and 0.5 to 2 g / L potassium chloride is provided.
- the present invention provides an enteric wash composition comprising 45-50 mmol polyethylene glycol, 270-290 mmol ascorbate component, 120-130 mmol sulfate, 40-50 mmol sodium chloride and 10-16 mmol potassium chloride. .
- the present invention provides a long wash composition comprising 150-170 g polyethylene glycol, 48-53 g ascorbate component, 17.5-18.5 g sodium sulfate, 2.5-3 g sodium chloride and 0.8-1.2 g potassium chloride as an anhydride. to provide.
- the present invention provides an enteric wash solution comprising 45-50 mM polyethylene glycol, 270-290 mM ascorbate component, 120-130 mM sulfate, 40-50 mM sodium chloride and 10-16 mM potassium chloride. .
- the present invention provides 150-170 g / L polyethylene glycol, 48-53 g / L ascorbate component, 17.5-18.5 g / L sodium sulfate as anhydride, 2.5-3 g / L sodium chloride and 0.8-1.2 g / An intestinal wash solution comprising L of potassium chloride is provided.
- the present invention comprises 45-50 mmol polyethylene glycol, 220-240 mmol ascorbic acid, 45-50 mmol sodium ascorbate, 120-130 mmol sulfate, 40-50 mmol sodium chloride and 10-16 mmol potassium chloride It provides a long wash composition.
- the present invention comprises 150-170 g polyethylene glycol, 39-43 g ascorbic acid, 9-10 g sodium ascorbate, 17.5-18.5 g sodium sulfate as anhydride, 2.5-3 g sodium chloride and 0.8-1.2 g potassium chloride It provides a long wash composition comprising a.
- the present invention comprises 45-50 mM polyethylene glycol, 220-240 mM ascorbic acid, 45-50 mM sodium ascorbate, 120-130 mM sulfate, 40-50 mM sodium chloride and 10-16 mM potassium chloride. To provide an intestinal wash solution.
- the present invention comprises 150-170 g / L polyethylene glycol, 39-43 g / L ascorbic acid, 9-10 g / L sodium ascorbate, 17.5-18.5 g / L sodium sulfate as anhydride, 2.5-3 g / L
- An intestinal wash solution comprising L of sodium chloride and 0.8 to 1.2 g / L of potassium chloride is provided.
- the present invention provides a long wash composition comprising 47.76 mmol of polyethylene glycol 3350, 278.16 mmol of ascorbate component, 126.76 mmol of sodium sulfate, 46.15 mmol of sodium chloride and 13.41 mmol of potassium chloride.
- the present invention provides an enteric wash composition
- the present invention provides an enteric wash solution comprising 47.76 mM polyethylene glycol 3350, 278.16 mM ascorbate component, 126.76 mM sodium sulfate, 46.15 mM sodium chloride and 13.41 mM potassium chloride.
- the present invention is a long wash solution comprising 160 g / L polyethylene glycol 3350, 50 g / L ascorbate component, 18 g / L sodium sulfate, 2.7 g / L sodium chloride and 1 g / L potassium chloride as an anhydride To provide.
- the present invention provides a long wash composition comprising 47.76 mmol of polyethylene glycol 3350, 230.68 mmol of ascorbic acid, 47.47 mmol of sodium ascorbate, 126.76 mmol of sodium sulfate, 46.15 mmol of sodium chloride and 13.41 mmol of potassium chloride.
- the present invention provides a long wash composition
- a long wash composition comprising 160 g polyethylene glycol 3350, 40.6 g ascorbic acid, 9.4 g sodium ascorbate, 18 g sodium sulfate as an anhydride, 2.7 g sodium chloride and 1 g potassium chloride.
- the present invention provides an enteric wash solution comprising 47.76 mM polyethylene glycol 3350, 230.68 mM ascorbic acid, 47.47 mM sodium ascorbate, 126.76 mM sodium sulfate, 46.15 mM sodium chloride and 13.41 mM potassium chloride.
- the present invention provides 160 g / L polyethylene glycol 3350, 40.6 g / L ascorbic acid, 9.4 g / L sodium ascorbate, 18 g / L sodium sulfate as anhydride, 2.7 g / L sodium chloride and 1 g / L It provides an enteric wash solution comprising potassium chloride.
- the present invention provides a long wash composition
- a long wash composition comprising polyethylene glycol, ascorbate component, sulfate, sodium chloride, potassium chloride
- the content of the polyethylene glycol may be 144 to 176 g or 152 to 168 g
- the ascorbate component The content of may be 45 to 55 g or 47.5 to 52.5 g
- the content of the sulfate may be 16.2 to 19.8 g or 17.1 to 18.9 g as an anhydride
- the content of sodium chloride is 2.43 to 2.97 g or 2.57 to 2.84 g
- the potassium chloride content may be 0.9 to 1.1 g or 0.95 to 1.05.
- the content of ascorbic acid may be 36.54 to 44.66 g or 38.75 to 42.63 g, and the content of sodium ascorbate is 8.46 to 10.34 g or 8.93 to 9.87 g Can be.
- the sulfate may be sodium sulfate.
- the present invention provides a long wash solution containing polyethylene glycol, ascorbate component, sulfate, sodium chloride, potassium chloride, the content of the polyethylene glycol may be 144 to 176 g / L or 152 to 168 g / L,
- the content of ascorbate component can be 45 to 55 g / L or 47.5 to 52.5 g / L
- the content of the sulfate can be 16.2 to 19.8 g / L or 17.1 to 18.9 g / L as an anhydride
- the sodium chloride The content of may be 2.43 to 2.97 g / L or 2.57 to 2.84 g / L
- the content of the potassium chloride may be 0.9 to 1.1 g / L or 0.95 to 1.05 / L.
- the content of ascorbic acid may be 36.54 to 44.66 g / L or 38.75 to 42.63 g / L, and the content of sodium ascorbate is 8.46 to 10.34 g / L Or 8.93 to 9.87 g / L.
- the sulfate may be sodium sulfate.
- the enteric cleaning composition or enteric cleaning solution of the present invention may further include a sweetening agent and / or flavoring agent as an additive.
- the sweetener saccharin that exhibits sweetening effect and fast solubility even in a small amount in addition to glucose, sucrose, dextrose, fructose and maltose, which are common sugars.
- Saccharin sodium, xylitol, sorbitol, mannitol, mannitol, maltitol, lactitol, isomalt, stevioside, erythritol ), Aspartame, acesulfame potassium, sucralose may be used in combination of one or more selected from the group containing.
- the sweetener may include 0.03 to 3 parts by weight based on 100 parts by weight of polyethylene glycol.
- flavoring agents may be further included in addition to the sweetener to improve patient compliance.
- the flavoring agent may be included in an amount of 0.01 to 3 parts by weight based on 100 parts by weight of polyethylene glycol, and may be included in a liquid, powder or clathrate form.
- the long wash solution of the present invention may be a solution containing sodium ions (Na +), potassium ions (K +) and / or chloride ions (Cl ⁇ ).
- the sodium ion concentration may be 200 to 500 mEq / L, specifically 300 to 400 mEq / L
- the potassium ion concentration may be 5 to 30 mEq / L, specifically 10 to 20 mEq / L
- the chloride ion concentration may be 30 to 90 mEq / L, specifically 40 to 80 mEq / L.
- the sodium ion concentration of the enteric wash solution of the present invention may be 400 mEq / L or less, specifically 370 mEq / L or less, more specifically 350 mEq / L or less, and potassium ion concentration may be 20 mEq / L or less It may be, specifically 16 mEq / L or less, more specifically 14 mEq / L or less, chloride ion concentration may be 80 mEq / L or less, specifically 70 mEq / L or less, more specifically 60 mEq It may be less than / L.
- Enteric solutions containing high concentrations of sodium may present serious problems with regard to safety, drinking and compliance, the enteric cleaning solutions of the present invention can solve such problems by including a suitable range of electrolytes. It is also important to provide an enteric wash solution with an appropriate electrolyte ion concentration because oversorption of ascorbate components by sodium ions and oversorption of sodium by chlorine ions can occur.
- the enteric wash solution of the present invention is hypertonic.
- the osmolality of the intestinal wash solution may be provided as an actual value or a theoretical value.
- the osmotic pressure value of the enteric wash solution of the present invention may be 700 to 1100 mOsmol / kg, specifically 800 to 1000 mOsmol / kg, more specifically 850 to 900 mOsmol / kg.
- the osmotic theoretical value is calculated based on the components constituting the enteric wash solution of the present invention, and may be calculated as follows:
- Osmotic theoretical value (mOsmol / kg) ⁇ ⁇ Amount of solute in solution (mg) / Molecular weight of solute * Dissociation constant (number of species produced per mol of solute) ⁇
- the osmotic pressure value of the enteric wash composition of the present invention is calculated as shown in Table 1 below.
- the osmotic pressure value is not necessarily the same as the actually measured osmotic pressure value, and may vary depending on the long wash solution to be measured.
- the osmotic pressure reading of the long wash solution of the present invention may be 1000 to 2000 mOsmol / kg, specifically 1200 to 1800 mOsmol / kg, more specifically 1400 to 1700 mOsmol / kg.
- the osmotic pressure value of the enteric wash solution of the present invention can be measured using a freezing point depression method, but is not limited thereto.
- the osmotic pressure of the enteric wash solution of the present invention can be provided as an estimated value, the range of the estimated value can be derived through experiments.
- the osmotic pressure estimate of the enteric wash solution of the present invention may be 1000 to 2000 mOsmol / kg, specifically 1300 to 1800 mOsmol / kg, more specifically 1400 to 1700 mOsmol / kg.
- the osmotic pressure estimate is a value that can compensate for the difference between the theoretical value and the measured value, taking into account the weight of the osmotic force in the long cleaning solution of polyethylene glycol.
- the osmotic pressure estimate can be calculated as follows.
- Osmotic pressure estimate (mOsmol / kg) ⁇ amount of polyethylene glycol in solution (mg) / molecular weight of polyethylene glycol * dissociation constant (number of species produced per mol of polyethylene glycol) * weight (polyethylene glycol amount ( g) 10%) ⁇ + ⁇ amount of sulfate in solution (mg) / molecular weight of sulfate * dissociation constant (number of species produced per mol of sulfate) ⁇ + ⁇ amount of sodium chloride in solution (mg) / Molecular weight of sodium chloride * Dissociation constant (number of species produced per mol of sodium chloride) ⁇ + ⁇ Amount of potassium chloride in solution (mg) / Molecular weight of potassium chloride * Dissociation constant (created per mol of potassium chloride) Number of species to be collected) ⁇ + ⁇ amount of ascorbic acid in the solution (mg) / molecular weight of ascorbic acid * dissociation constant (
- the osmotic pressure estimate of the enteric wash solution of the present invention may be calculated as shown in Table 2 below.
- the long wash composition or solution of the present invention wherein the weight ratio of polyethylene glycol and ascorbate component is specified as 2.5: 1 to 4: 1 and the ascorbate component is specified ascorbic acid and sodium ascorbate in weight ratio 3.5: 1 to 5: 1. Is characterized by an excellent long-cleaning effect and increased safety.
- the enteric wash compositions or solutions of the present invention are intestinal in animal studies compared to compositions or solutions having different content ratios of polyethyleneglycol and ascorbate or ascorbic acid and sodium ascorbate in the ascorbate component.
- Example 2 In addition to excellent washing effect (Experimental Examples 1 and 2), it is excellent in safety due to the small number of sudden changes in the blood test (Experimental Example 2), and superior intestinal cleansing effect in clinical trials compared to the commercially available long cleansing composition And safety was confirmed (Experimental Example 3), it was confirmed that it has an excellent effect in both the ease of administration (Experimental Example 4) and preference (Experimental Example 5) evaluation in clinical trials. Etc.), and may be provided in various forms such as granules, tablets, capsules or liquids, and the components included in the composition may be the same or different. It may be provided in other forms.
- the long wash composition is a solid preparation such as powder or granules
- the composition may be dissolved in water, and when the long wash composition is provided as a tablet or capsule, it may be taken with a sufficient amount of water.
- Each component of the long wash composition of the present invention may be provided separately and / or packaged together.
- the ascorbate component is preferably packaged separately from other components according to chemical properties.
- the long-wash composition of the present invention is appropriately packaged by dividing the total dose according to the number of doses.
- the long wash composition of the present invention may be provided by packaging a total dose at a time, and may be provided by dividing the total dose into two or more packages.
- Intestinal cleansing compositions of the present invention may be administered in one time at a time (called non-divided or divided doses) or divided into several time points (called divided or two-day divided doses).
- the enteric wash composition of the present invention may be taken for several hours in the evening before the test or in the morning of the test day. Specifically, a portion of the total dose may be taken and after a certain time, for example, after 0.5 to 3 hours.
- the enteric wash composition of the present invention may take a portion on the evening before the test and the rest on the morning of the test day.
- each dose may be taken within a certain time. Specifically, each dose may be taken within 2 hours, within 1 hour or within 30 minutes.
- the present invention provides an enteric cleansing composition and / or enteral cleansing solution in which a sufficient amount of enteral cleansing can be achieved even with a small dose of enteric cleansing agent, wherein the enteric cleansing solution of the present invention is in a dose of about 1200 mL or less, Specifically, the dose may be 1100 mL or less, more specifically 1000 mL or less.
- additional water may be taken after taking the enteric wash solution.
- a certain amount for example, a dose of 0.5 to 2 L, specifically a dose of 1 to 1.5 L, more specifically a dose of 1 L or less, may be additionally taken.
- Additional water may be taken after the intestinal wash solution is taken or between the intestinal wash solutions.
- the enteric cleaning composition of the present invention can be used for the treatment of constipation.
- the present invention also provides a method for intestinal lavage, comprising administering to the subject a therapeutically effective amount of said enteric cleansing composition.
- the present invention also provides a method of treating constipation, comprising administering to a subject a therapeutically effective amount of said enteric cleansing composition.
- the invention also provides the use of said composition for the manufacture of a medicament for the treatment of bowel lavage or constipation.
- the bowel cleansing compositions and solutions of the present invention have a small dose and have a good taste, thus improving the convenience of taking medication and compliance with the medications, and exhibiting a safe and excellent bowel cleansing effect, and thus can be used as an effective bowel cleanser.
- Figure 2 is a visual confirmation of the intestinal lavage of the group not administered the bowel cleansing composition, it is confirmed that the stool intact intact.
- the long wash composition of the present invention was prepared in Examples 1 to 4 according to the ingredients and contents in Table 3 below.
- Example 1 Example 2
- Example 3 Example 4 PEG3350 160 140 150 170 Na 2 SO 4 18 16 17.5 18.5 NaCl 2.7 2.0 2.5 3.0 KCl 1.0 0.5 0.8 1.2 Ascorbic acid 40.6 36 39 43 Sodium ascorbate 9.4 8 9 10
- the long wash composition of Table 3 was prepared in Examples 1 to 4 solution by dissolving in water so that the volume of the chemical solution is 1 liter.
- Example 1 to Example 4 The molarity (mM) of the components contained in the solution and the molar ratio of the main components are shown in Table 4 below.
- the long cleansing compositions of Examples 1-4 may be provided in the form of two pouches (Pouch A without ascorbate component and Pouch B with ascorbate component), wherein Pouch A and You can take B by dissolving it in water to 1L together.
- the long wash composition of Example 1 may be provided in a form including pouch A and pouch B, as shown in Table 5 below, and may be provided in the same manner in the case of the long wash composition of Examples 2 to 4.
- the long cleaning composition of Examples 1 to 4 includes four pouches (pouch A (1), A (2) not containing ascorbate component, Pouch B (1) containing ascorbate component), B (2)) may be provided, and the pouches A (1) and B (1) are dissolved in water to make 500 mL together, and A (2) and B (2) are taken together in 500 mL Can be taken by dissolving in water.
- the long wash composition of Example 1 may be provided in a form including pouches A (1), A (2), B (1), and B (2), as shown in Tables 6 and 7 below.
- the long wash compositions of 2 to 4 may also be provided in the same manner.
- Pouch A (1) Pouch B (1) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 80 9 1.35 0.5 25
- Pouch A (2) Pouch B (2) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 80 9 1.35 0.5 25
- the long-wash composition of Examples 1 to 4 includes the following eight pouches (pouches A (1), A (2), A (3), A (4) and ascorbic) without the ascorbate component It may be provided in a form that includes pouches B (1), B (2), B (3), and B (4)) containing the bait ingredient, together with 250 mL of pouches A (1) and B (1). Dissolve in water so that A (2) and B (2) together, A (3) and B (3) together, A (4) and B (4) together, 250 mL each Can be taken by dissolving in water.
- pouches A (1), A (2), (B1), and (B2) are dissolved in water so as to be 500 ml, and the pouches A (3), A (4), (B3) and (B4) are taken. You can take it in water so that it is 500 ml together.
- the long cleansing composition of Example 1 is a pouch A (1), A (2), A (3), A (4), B (1), B (2), B as shown in Tables 8 to 11 below.
- (3), B (4) may be provided in the form, and in the case of the long-wash composition of Examples 2 to 4 may be provided in the same manner.
- Pouch A (1) Pouch B (1) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 40 4.5 0.675 0.25 12.5
- Pouch A (2) Pouch B (2) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 40 4.5 0.675 0.25 12.5
- Pouch A (3) Pouch B (3) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 40 4.5 0.675 0.25 12.5
- Pouch A (4) Pouch B (4) PEG3350 Na 2 SO 4 NaCl KCl Ascorbate Ingredients 40 4.5 0.675 0.25 12.5
- An animal model was used to confirm the intestinal cleansing effect of the intestinal cleansing solution of the present invention. Specifically, 20 mL of the enteric washing solution of Example 1 was administered to Sprague-Dawley rats. Blood loss and lethality occurred 6 hours after the start of administration. Thereafter, the large intestine was removed to check the degree of intestinal lavage.
- a comparative bowel wash solution was prepared to compare the bowel wash effect and safety in the animal model.
- compositions of Example 1 and Comparative Examples 1 to 4 are shown in Table 12 below, and were prepared by dissolving in water so that the total volume of the chemical solution was 1L.
- Comparative Example 1 in Table 12 and Table 13 had a polyethylene glycol content (80 g) of half the Example 1 solution (160 g) while the concentration of ascorbate component (570.83 mM) was determined in Example 1 solution (278.16 mM). It's twice the level.
- intestinal cleanliness was evaluated according to the criteria of Table 14, and the results are shown in Table 15 below.
- Blood tests include AST (Asparate aminotransferase), ALT (Alkaine aminotransferase), blood urea nitrogen (BUN), creatinine (Creatinine), red blood cells (Red blood cell (RBC), hemoglobin (HGB), mean red blood cell hemoglobin concentration (Mean corpuscular) Hemoglobin concentration (MCHC), hematocrit (HCT), etc. were measured, and the results showed that the subjects who took the solution of Example 1 were significantly lower than the subjects who took the solution of Comparative Example 1. Confirmed.
- the bowel cleansing solution according to the content ratio of polyethylene glycol and ascorbate component of the present invention is excellent in both the bowel cleansing effect and safety, and can be usefully used as a bowel cleansing solution.
- Comparative Example 2 solution of Table 12 and Table 13 and Example 1 solution is the same polyethylene glycol content and ascorbate component content, while Example 1 solution is the molar ratio of ascorbic acid and sodium ascorbate contained in the ascorbate component It is about 4.86: 1, while the solution of Comparative Example 2 is 1: 1, and the molar ratios are different from each other.
- Example 3 and 4 and Table 1 of Table 12 and Table 13 and Example 1 have the same polyethyleneglycol content and ascorbate component content, but the solution of Example 1 is composed of ascorbic acid and sodium ascorbate contained in the ascorbate component.
- the molar ratio is about 4.86: 1
- Comparative Example 3 and Comparative 4 solutions are 1: 1.5 and 1: 5.67 respectively, differing in molar ratio from each other.
- Example 1 (6), for a total of 18 rats Jang graininess of Example 3 (6) and Comparative Example 4 (6) taking group was measured according to the criteria of Table 14, the results are shown in Table 17 below.
- Example 1 and Comparative Examples 2, 3, and 4 solutions contained the same amount of polyethylene glycol and ascorbate components, while Example 1 solution contained Comparative Examples 2 different in ascorbic acid and sodium ascorbate ratios. It can be seen that the long-wash ability is superior to the 3, 4 solution.
- the blood of the rats taking the Example 1 solution and the Comparative Examples 2, 3, 4 solution to measure the safety when taking the long-wash solution The test was performed. As a result, it was confirmed that blood AST level and Na + level change of rats taking the solutions of Comparative Examples 2, 3 and 4 were much higher than those of the rats taking the solution of Example 1.
- Example 1 The solution was confirmed to be a long wash solution with higher safety than the Comparative Examples 2, 3 and 4 solutions.
- the intestinal cleansing solution according to the ascorbic acid and sodium ascorbate content ratio of the present invention is excellent in both the long cleansing effect and safety, it can be usefully used as a solution for intestinal washing.
- Example 1 After the administration of the enteric wash solution of Example 1 and the commercial product, kulprep acid, which was optionally selected, the intestinal cleansing effect was confirmed.
- the intestinal cleansing solution of Example 1 was to take 1 L
- kulprep acid is a product taking 2 L of the drug solution.
- Example 1 and the composition of kulprep acid is shown in Table 18 below.
- Test Group 1 takes 500 mL of the long wash solution of Example 1 for about 30 minutes, 500 mL of the long wash solution of Example 1 after about 1 to 2 hours, and additionally water 1 L was allowed to drink. After taking the wash solution, water was divided into 500 mL and drink.
- Test groups 2 and 3 took 500 mL of the intestinal wash solution of Example 1 (for about 30 minutes) and 1 L of kulprep acid (for about 1 hour) and drink 500 mL of water on the evening before the test, respectively. In the morning, 500 mL of the intestinal wash solution of Example 1 (for about 30 minutes) and 1 L of kulprep acid (for about 1 hour) were taken and each of 500 mL of water was taken.
- a grade means 'empty, clean' or 'transparent liquid' in all areas of the colon (rectal, S-colon, descending colon, transverse colon, ascending colon), which means very good cleanliness.
- the intestinal success rate of the test group taking the intestinal cleansing solution of Example 1 was higher than that of the test group taking the cool prep acid, and the number of patients rated as A was greater than the test group 3 Much more in 1 and 2.
- the A grade rate of the test group 2 is 80.00%, much higher than 55.21% of the test group 3.
- the cool prep acid is a product that should take 2L of the liquid solution
- the intestinal cleansing composition of Example 1 was only 1L of the liquid solution
- the long-washing composition of the present invention showed an excellent long-cleaning effect than a commercial product. Can be.
- the intestinal cleansing composition of the present invention is a composition having a superior effect of excellent cleansing force compared to the commercial product of kulprep acid and can increase the accuracy of endoscopy and disease diagnosis Able to know.
- the bowel cleansing solution of the present invention is clinically excellent in both the bowel cleansing effect and safety, and thus can be usefully used as a bowel cleansing solution.
- Example 1 Ease of taking the intestinal cleansing solution of Example 1 was evaluated by categorizing “Yes” and “No”. As a result, all patients except Test 1 in Test Group 1 and all patients in Test Group 2 “ Yes. ”
- Example 2 In evaluating the taste of the intestinal cleansing solution of Example 1, 80% and 87% of patients in Test Group 1 and Test Group 2 responded that the taste was good or okay, respectively. 4% and 1% in test group 2.
- Example 1 Comparative Example 2 and Comparative Example 5
- the composition was prepared by dissolving the composition in Example 1, Comparative Example 2 and Comparative Example 5 so that the total volume of the chemical solution, the specific composition is shown in Table 21 below.
- the molar ratios of ascorbic acid and sodium ascorbate contained in the solution of Example 1, Comparative Example 2 and Comparative Example 5 are 4.86: 1, 1: 1 and 1: 4.86, respectively, and the moles of ascorbate components included in each solution.
- the concentration is about 278 mM.
- the long wash solutions used in the preference evaluation included the same amount of additives (flavours, sweeteners).
- t-test verification was performed by adding preference scores. The lower the preference sum score, the higher the preference.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
성분 | 분자량(MW) | 함량 (g) | 해리상수 | 삼투압 이론값(mOsmol/kg) |
PEG3350 | 3350 | 160 | 1 | 160*1000/3350*1 = 48 |
Na 2SO 4 | 142 | 18 | 3 | 18*1000/142*3 = 380 |
NaCl | 58.5 | 2.7 | 2 | 2.7*1000/58.5*2 = 92 |
KCl | 74.55 | 1 | 2 | 1*1000/74.55*2 = 27 |
아스코르브산나트륨 | 198 | 9.4 | 2 | 9.4*1000/198*2 = 95 |
아스코르브산 | 176 | 40.6 | 1 | 40.6*1000/176*1 = 231 |
총합 | 873 |
성분 | 분자량(MW) | 함량 (g) | 해리상수 | 가중치 | 삼투압 추정값(mOsmol/kg) |
PEG3350 | 3350 | 160 | 1 | 16 | 160*1000/3350*1*16 = 764 |
Na 2SO 4 | 142 | 18 | 3 | - | 18*1000/142*3 = 380 |
NaCl | 58.5 | 2.7 | 2 | - | 2.7*1000/58.5*2 = 92 |
KCl | 74.55 | 1 | 2 | - | 1*1000/74.55*2 = 27 |
아스코르브산나트륨 | 198 | 9.4 | 2 | - | 9.4*1000/198*2 = 95 |
아스코르브산 | 176 | 40.6 | 1 | - | 40.6*1000/176*1 = 231 |
총합 | 1589 |
성분 (g) | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 |
PEG3350 | 160 | 140 | 150 | 170 |
Na 2SO 4 | 18 | 16 | 17.5 | 18.5 |
NaCl | 2.7 | 2.0 | 2.5 | 3.0 |
KCl | 1.0 | 0.5 | 0.8 | 1.2 |
아스코르브산 | 40.6 | 36 | 39 | 43 |
아스코르브산나트륨 | 9.4 | 8 | 9 | 10 |
성분 (mM) | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 |
PEG3350 | 47.76 | 41.79 | 44.78 | 50.75 |
Na 2SO 4 | 126.76 | 112.68 | 123.24 | 130.28 |
NaCl | 46.15 | 34.19 | 42.74 | 51.28 |
KCl | 13.41 | 6.71 | 10.73 | 16.10 |
아스코르베이트 성분 | 278.16 | 244.95 | 267.05 | 294.82 |
PEG : 아스코르베이트 성분 몰 비 | 1 : 5.82 | 1 : 5.86 | 1 : 5.96 | 1 : 5.81 |
아스코르브산 : 아스코르브산나트륨몰 비 | 4:86 : 1 | 5.06 : 1 | 4.88 : 1 | 4.84 : 1 |
PEG : Na 2SO 4 몰 비 | 1 : 2.65 | 1 : 2.70 | 1 : 2.75 | 1 : 2.57 |
파우치 A | 파우치 B | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
160 | 18 | 2.7 | 1.0 | 50 |
파우치 A(1) | 파우치 B(1) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
80 | 9 | 1.35 | 0.5 | 25 |
파우치 A(2) | 파우치 B(2) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
80 | 9 | 1.35 | 0.5 | 25 |
파우치 A(1) | 파우치 B(1) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
40 | 4.5 | 0.675 | 0.25 | 12.5 |
파우치 A(2) | 파우치 B(2) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
40 | 4.5 | 0.675 | 0.25 | 12.5 |
파우치 A(3) | 파우치 B(3) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
40 | 4.5 | 0.675 | 0.25 | 12.5 |
파우치 A(4) | 파우치 B(4) | |||
PEG3350 | Na 2SO 4 | NaCl | KCl | 아스코르베이트 성분 |
40 | 4.5 | 0.675 | 0.25 | 12.5 |
성분 (g) | 실시예 1 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 |
PEG3350 | 160 | 80 | 160 | 160 | 160 |
Na 2SO 4 | 18 | 18 | 18 | 18 | 18 |
NaCl | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 |
KCl | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
아스코르브산 | 40.6 | 83.32 | 24.48 | 19.58 | 7.34 |
아스코르브산나트륨 | 9.4 | 19.29 | 27.54 | 33.05 | 46.82 |
전체 약액 부피 | 1 L |
성분 (mM) | 실시예 1 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 |
PEG3350 | 47.76 | 23.88 | 47.76 | 47.76 | 47.76 |
Na 2SO 4 | 126.76 | 126.76 | 126.76 | 126.76 | 126.76 |
NaCl | 46.15 | 46.15 | 46.15 | 46.15 | 46.15 |
KCl | 13.41 | 13.41 | 13.41 | 13.41 | 13.41 |
아스코르베이트 성분 | 278.16 | 570.83 | 278.18 | 278.17 | 278.17 |
PEG : 아스코르베이트 성분 몰 비 | 1 : 5.82 | 1 : 23.9 | 1 : 5.82 | 1 : 5.82 | 1 : 5.82 |
아스코르브산 : 아스코르브산나트륨몰 비 | 4.86 : 1 | 4.86 : 1 | 1 : 1 | 1 : 1.5 | 1 : 5.67 |
PEG : Na 2SO 4 몰 비 | 1: 2.65 | 1: 5.31 | 1: 2.65 | 1: 2.65 | 1: 2.65 |
등급 | 기준 |
1 등급 | 깨끗 또는 투명한 액체만 존재 |
2 등급 | 소량의 갈색 액체가 존재하며 반-고체 상태의 대변은 거의 없는 상태 |
3 등급 | 갈색 액체, 완전히 제거 가능한 반-고체 대변 존재 |
4 등급 | 부분적으로 제거 가능한 반-고체 대변 존재 |
5 등급 | 제거 불가능하고 딱딱한 대변 존재 |
장 세척도 (마리) | |||||
1 등급 | 2 등급 | 3 등급 | 4 등급 | 5 등급 | |
실시예 1 | 3 | 2 | 1 | 0 | 0 |
비교예 1 | 0 | 3 | 2 | 1 | 0 |
장 세척도 (마리) | |||||
1 등급 | 2 등급 | 3 등급 | 4 등급 | 5 등급 | |
실시예 1 | 3 | 2 | 1 | 0 | 0 |
비교예 2 | 0 | 1 | 5 | 0 | 0 |
장 세척도 (마리) | |||||
1 등급 | 2 등급 | 3 등급 | 4 등급 | 5 등급 | |
실시예 1 | 4 | 1 | 1 | 0 | 0 |
비교예 3 | 0 | 3 | 3 | 0 | 0 |
비교예 4 | 0 | 3 | 3 | 0 | 0 |
성분 | 실시예 1 (g) | 쿨프렙산 (g) |
PEG3350 | 160 | 200 |
Na 2SO 4 | 18 | 15 |
NaCl | 2.7 | 5.38 |
KCl | 1.0 | 2.03 |
아스코르브산 | 40.6 | 9.4 |
아스코르브산나트륨 | 9.4 | 11.8 |
약액 부피 | 1L | 2L |
환자군 | 시험군 1 | 시험군 2 | 시험군 3 | |
환자수 | 94 | 95 | 96 | |
장세척제 | 실시예 1의 장세척 용액 | 실시예 1의 장세척 용액 | 쿨프렙산 | |
복용방법 | 당일 분할 투여 | 분할 투여 | 분할 투여 | |
정결도 등급별 환자수 | A | 62 (65.96%) | 76 (80.00%) | 53 (55.21%) |
B | 29 (30.85%) | 18 (18.95%) | 38 (39.58%) | |
C | 3 (3.19%) | 0 (0%) | 5 (5.21%) | |
D | 0 (0.00%) | 1 (1.05%) | 0 (0.00%) | |
성공한 환자 비율 | 96.81% | 98.95% | 94.79% |
A 등급 환자 비율 | |||
시험군 1 | 시험군 2 | 시험군 3 | |
상행 결장 | 75.53% (71/94명) | 83.16% (79/95명) | 62.50% (60/96명) |
횡행 결장 | 88.30% (83/94명) | 94.74% (90/95명) | 76.04% (73/96명) |
하행 결장 | 92.55% (87/94명) | 90.53% (86/95명) | 82.29% (79/96명) |
S-결장 | 87.23% (82/94명) | 89.47% (85/95명) | 81.25% (78/96명) |
직장 | 91.49% (86/94명) | 92.63% (88/95명) | 80.21% (77/96명) |
성분 (g) | 실시예 1 | 비교예 2 | 비교예 5 |
PEG3350 | 160 | 160 | 160 |
Na 2SO 4 | 18 | 18 | 18 |
NaCl | 2.7 | 2.7 | 2.7 |
KCl | 1.0 | 1.0 | 1.0 |
아스코르브산 | 40.6 | 24.48 | 8.35 |
아스코르브산나트륨 | 9.4 | 27.54 | 45.67 |
약액의 부피 | 1 L |
Claims (21)
- 폴리에틸렌글리콜(PEG) 및 아스코르베이트 성분을 포함하고, 상기 폴리에틸렌글리콜 및 아스코르베이트 성분의 중량비는 2.5:1 내지 4:1이고, 상기 폴리에틸렌글리콜 성분의 함량은 140 g 이상이고, 상기 아스코르베이트 성분의 함량은 55 g 미만이고, 상기 아스코르베이트 성분은 중량비 3.5:1 내지 5:1의 아스코르브산 및 아스코르브산나트륨을 포함하는 장세척 조성물.
- 제1항에 있어서, 폴리에틸렌글리콜의 함량은 140 g 내지 180 g인 장세척 조성물.
- 제1항에 있어서, 아스코르베이트 성분의 함량은 45 g 이상 55 g 미만인 장세척 조성물.
- 제1항에 있어서, 아스코르브산의 함량은 35 내지 45 g이고, 아스코르브산나트륨의 함량은 8 내지 11 g인 장세척 조성물.
- 제1항에 있어서, 황산나트륨을 포함하고, 폴리에틸렌글리콜 및 황산나트륨의 중량비는 7:1 내지 12:1인 장세척 조성물.
- 제5항에 있어서, 황산나트륨의 함량은 무수물로써 16 내지 20 g인 장세척 조성물.
- 제1항에 있어서, 2 내지 3.5 g의 염화나트륨을 포함하는 장세척 조성물.
- 제1항에 있어서, 0.5 내지 2 g의 염화칼륨을 포함하는 장세척 조성물.
- 폴리에틸렌글리콜(PEG) 및 아스코르베이트 성분을 포함하고, 상기 폴리에틸렌글리콜 및 아스코르베이트 성분의 몰 비는 1:4.5 내지 1:7.5이고, 상기 폴리에틸렌글리콜의 함량은 40 mM 이상이고, 상기 아스코르베이트 성분의 함량은 300 mM 미만이고, 상기 아스코르베이트 성분은 몰 비 4:1 내지 6:1의 아스코르브산 및 아스코르브산나트륨을 포함하는 장세척 용액.
- 제9항에 있어서, 폴리에틸렌글리콜의 함량은 40 mM 내지 55 mM인 장세척 용액.
- 제9항에 있어서, 아스코르베이트 성분의 함량은 250 mM 이상 300 mM 미만인 장세척 용액.
- 제9항에 있어서, 아스코르브산의 함량은 200 내지 255 mM이고, 아스코르브산나트륨의 함량은 40 내지 55 mM인 장세척 조성물.
- 제9항에 있어서, 황산염을 포함하고, 폴리에틸렌글리콜 및 황산염의 몰 비가 1:2 내지 1:3.5인 장세척 용액.
- 제9항에 있어서, 110 내지 140 mM의 황산염을 포함하는 장세척 용액.
- 제9항에 있어서, 35 내지 60 mM의 염화나트륨을 포함하는 장세척 용액.
- 제9항에 있어서, 7 내지 27 mM의 염화칼륨을 포함하는 장세척 용액.
- 제9항 또는 제15항에 있어서, 나트륨 이온 농도가 200 내지 500 mEq/L인 장세척 용액.
- 제16항에 있어서, 칼륨 이온 농도가 5 내지 30 mEq/L인 장세척 용액.
- 제15항 또는 제16항에 있어서, 염화 이온 농도가 30 내지 90 mEq/L인 장세척 용액.
- 제9항에 있어서, 상기 장세척 용액은 고장성인 장세척 용액.
- 제9항에 있어서, 상기 장세척 용액은 1200 mL 이하의 용량으로 복용되는 것인 장세척 용액.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020128710A RU2790700C2 (ru) | 2018-02-01 | 2019-02-01 | Композиция для очищения кишечника |
CN201980010065.5A CN111670039A (zh) | 2018-02-01 | 2019-02-01 | 肠清洁组合物 |
JP2020542006A JP7254820B2 (ja) | 2018-02-01 | 2019-02-01 | 腸管洗浄用組成物 |
CA3088145A CA3088145A1 (en) | 2018-02-01 | 2019-02-01 | Bowel cleansing composition |
EP19747088.3A EP3747447A4 (en) | 2018-02-01 | 2019-02-01 | INTESTINAL CLEANING COMPOSITION |
US16/965,182 US11510884B2 (en) | 2018-02-01 | 2019-02-01 | Bowel cleansing composition |
PH12020551100A PH12020551100A1 (en) | 2018-02-01 | 2020-07-17 | Bowel cleansing composition |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180013113 | 2018-02-01 | ||
KR10-2018-0013113 | 2018-02-01 | ||
KR10-2018-0066282 | 2018-06-08 | ||
KR20180066282 | 2018-06-08 | ||
KR1020180119830A KR101981069B1 (ko) | 2018-02-01 | 2018-10-08 | 장세척 조성물 |
KR10-2018-0119830 | 2018-10-08 | ||
KR10-2019-0002739 | 2019-01-09 | ||
KR1020190002739A KR20190093501A (ko) | 2018-02-01 | 2019-01-09 | 장세척 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019151829A1 true WO2019151829A1 (ko) | 2019-08-08 |
Family
ID=67478385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/001456 WO2019151829A1 (ko) | 2018-02-01 | 2019-02-01 | 장세척 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019151829A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070001280A (ko) * | 2004-04-23 | 2007-01-03 | 노어긴 유럽 비브이 | 폴리에틸렌글리콜 및 전해질을 포함하는 압축 약학적조성물 |
JP2008001724A (ja) * | 2002-10-25 | 2008-01-10 | Norgine Europe Bv | 結腸洗浄組成物 |
KR20120070560A (ko) * | 2009-07-17 | 2012-06-29 | 노어긴 비.브이. | 장 세척 조성물과 관련된 장 세척 조성물의 개선 |
KR20140044628A (ko) * | 2012-10-05 | 2014-04-15 | 주식회사태준제약 | 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물 |
KR101771586B1 (ko) * | 2012-09-11 | 2017-08-25 | 노어긴 비.브이. | Peg 및 아스코르베이트를 포함하는 조성물 |
-
2019
- 2019-02-01 WO PCT/KR2019/001456 patent/WO2019151829A1/ko unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008001724A (ja) * | 2002-10-25 | 2008-01-10 | Norgine Europe Bv | 結腸洗浄組成物 |
KR20070001280A (ko) * | 2004-04-23 | 2007-01-03 | 노어긴 유럽 비브이 | 폴리에틸렌글리콜 및 전해질을 포함하는 압축 약학적조성물 |
KR20120070560A (ko) * | 2009-07-17 | 2012-06-29 | 노어긴 비.브이. | 장 세척 조성물과 관련된 장 세척 조성물의 개선 |
KR101771586B1 (ko) * | 2012-09-11 | 2017-08-25 | 노어긴 비.브이. | Peg 및 아스코르베이트를 포함하는 조성물 |
KR20140044628A (ko) * | 2012-10-05 | 2014-04-15 | 주식회사태준제약 | 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3747447A4 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0498069B1 (en) | New use of peptide derivative | |
US20020173485A1 (en) | Compositions and methods for the treatment or prevention of inflammation | |
CN101522167A (zh) | 一种通过跨粘膜途径进行活性成分给药的盖伦制剂 | |
US8895051B2 (en) | Flavoring systems for pharmaceutical compositions and methods of making such compositions | |
WO1985002119A1 (en) | Ddavp antidiuretic and method therefor | |
WO2014054880A1 (ko) | 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물 | |
WO2019151829A1 (ko) | 장세척 조성물 | |
JP4535234B2 (ja) | 腸管洗浄製剤 | |
KR100746444B1 (ko) | 설사-우세형 과민성 대장 증후군의 치료제 | |
US11510884B2 (en) | Bowel cleansing composition | |
PT97964A (pt) | Processo para a producao de composicoes farmaceuticas de somatostatina de reabsorcao aumentada, e sua utilizacao | |
WO2022211460A1 (ko) | Sars-cov-2 감염증 치료용 약학 조성물 | |
WO2022146089A1 (ko) | 장세척을 위한 경구용 고형제제 | |
WO2013119002A1 (ko) | 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물 | |
Salim | Use of scavenging oxygen‐derived free radicals to protect the rat against aspirin‐and ethanol‐induced erosive gastritis | |
AU617801B2 (en) | Pharmaceutical solutions of triamterene | |
JPH03284620A (ja) | 腸管洗浄用組成物 | |
RU2790700C2 (ru) | Композиция для очищения кишечника | |
WO2023113487A1 (ko) | 펙수프라잔 주사제 조성물 용법용량 | |
US20100130475A1 (en) | Preventive or therapeutic agent for inflammatory bowel diseases | |
WO2022182173A1 (ko) | 장세척을 위한 조성물 | |
JPH0445494B2 (ko) | ||
WO1999018975A1 (fr) | Medicament contre la leishmaniose, contenant un derive de glucopyranose en tant que principe actif | |
KR20000046974A (ko) | 아세글루타미드 알루미늄의 경구 투여용 제제 조성물ㅇ | |
JPH02142728A (ja) | 抗アテローム性動脈硬化症剤及び抗過コレステリン血症剤としてのピラゾロピリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19747088 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3088145 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020542006 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019747088 Country of ref document: EP Effective date: 20200901 |